Intraoperative cell salvage in radical retropubic prostatectomy

Gray, Christine L.; Amling, Christopher L.; Polston, Gregory R; Powell, Curt R.; Kane, Christopher J.

doi:10.1016/s0090-4295(01)01365-6

Cited by 68 publications

(80 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is generally accepted that the presence of seminal vesicle invasion (SVI) in a resected specimen is an unfavourable prognostic factor in prostate cancer [1][2][3]. SVI has been reported in 5-13.6% of recent radical prostatectomy specimens [4][5][6]. Various studies have assessed the prediction of recurrence and prognosis in patients with prostate cancer and SVI treated by radical prostatectomy.…”

Section: Standardization Of Radical Cystectomymentioning

confidence: 99%

Red‐cell salvage in urological surgery

2004

View full text Add to dashboard Cite

Section: Standardization Of Radical Cystectomymentioning

confidence: 99%

Red‐cell salvage in urological surgery

2004

View full text Add to dashboard Cite

“…There is no evidence to support the concern about the theoretical risk of cancer dissemination. [7][8][9] We have looked at the clinical and financial benefits of using ICS as a method of reducing the ABT requirements for our RRP patients. Patients in Group A received HBTs when indicated.…”

mentioning

confidence: 99%

Intraoperative red blood cell salvage and autologous transfusion during open radical retropubic prostatectomy: a cost–benefit analysis

Ubee

Kumar

Athmanathan

et al. 2011

annals

View full text Add to dashboard Cite

INTRODUCTION Open radical retropubic prostatectomy (RRP) has an average blood loss of over 1,000ml. This has been reported even from high volume centres of excellence. [1][2][3][4] We have looked at the clinical and financial benefits of using intraoperative cell salvage (ICS) as a method of reducing the autologous blood transfusion requirements for our RRP patients. MATERIALS AND METHODS Group A comprised 25 consecutive patients who underwent RRP immediately prior to the acquisition of a cell saver machine. Group B consisted of the next 25 consecutive patients undergoing surgery using the Dideco Electa (Sorin Group, Italy) cell saver machine. Blood transfusion costs for both groups were calculated and compared. RESULTS The mean postoperative haemoglobin was similar in both groups (11.1gm/dl in Group A and 11.4gm/dl in Group B). All Group B patients received autologous blood (average 506ml, range: 103-1,023ml). In addition, 5 patients (20%) in Group B received a group total of 16 units (average 0.6 units) of homologous blood. For Group A the total cost of transfusing the 69 units of homologous blood was estimated as £9,315, based on a per blood unit cost of £135. This cost did not include consumables or nursing costs. CONCLUSIONS We found no evidence that autologous transfusions increased the risk of early biochemical relapse or of disease dissemination. ICS reduced our dependence on donated homologous blood.

show abstract

“…64 Malignancy recurrence or metastases secondary to perioperative transfusion practices is a difficult field of study given the heterogeneity of the clinical circumstance, the type and stage of cancer, and the long follow-up times required. Nonetheless, 15 clinical studies have been published reporting outcomes on patients who received transfusion of ICS blood intraoperatively during malignancy surgery [64][65][66][67][68][69][70][71][72][73][74][75][76][77][78] (Table 3). The majority of these studies were single-centre non-randomized small studies where the outcome of patients who received intraoperative ICS blood was compared with historic or case controls.…”

Section: Clinical Experiencementioning

confidence: 99%

“…The majority of these studies were single-centre non-randomized small studies where the outcome of patients who received intraoperative ICS blood was compared with historic or case controls. Four of these were controlled studies comparing intraoperative transfusion of ICS blood with transfusion of preoperatively donated autologous blood 70,71 or transfusion of allogeneic blood or no blood. 73,78 It is critical to point out that the majority of studies (13/15) involved ICS blood that was transfused without the benefit of subsequent LR filtration or irradiation.…”

Section: Clinical Experiencementioning

confidence: 99%

“…Multiple surgical programs have continued to recognize both the potential benefit of autologous transfusion Cell salvage in oncologic surgery 1065 Table 3 Tumour recurrence in patients who received intraoperative autotransfusion of ICS blood during malignancy surgery-clinical studies and the potential harm of allogeneic transfusion, and they have persisted in offering ICS (± perioperative autologous donation) to their patients undergoing resection of malignancy. 66,69,70,72,74,76 This practice has afforded more than 20 years of experience from some of these teams who clearly have experienced benefit rather than detriment to their patients. The current body of in vitro evidence together with a growing clinical experience suggest that ICS should not be withheld from patients with malignancy.…”

Section: Evolution Of Practicementioning

confidence: 99%

See 1 more Smart Citation

Should intraoperative cell-salvaged blood be used in patients with suspected or known malignancy?

Trudeau

Waters

Chipperfield

2012

Can J Anesth/J Can Anesth

View full text Add to dashboard Cite

Should intraoperative cell-salvaged blood be used in patients with suspected or known malignancy? Les cellules sanguines épargnées en peropératoire doivent-elles être réutilisées chez des patients ayant des processus malins connus ou suspectés? Abstract Purpose Intraoperative cell salvage (ICS) is used as an alternative to allogeneic blood transfusion in an attempt to avoid or minimize the risks associated with allogeneic blood. Intraoperative cell salvage is generally avoided in surgeries where malignancy is confirmed or suspected due to concern for potential metastasis or cancer recurrence. The application of post-processing methods for ICS is hypothesized to eliminate this potential risk. The purpose of this narrative review is to examine the in vitro experimental evidence as it pertains to the removal of tumour cells from ICS blood and to review the clinical studies where ICS blood has been used in patients with malignancy. Source A search of the English literature for relevant articles published from 1973 to 2012 was undertaken using

show abstract

Intraoperative cell salvage in radical retropubic prostatectomy

Cited by 68 publications

References 26 publications

Red‐cell salvage in urological surgery

Red‐cell salvage in urological surgery

Intraoperative red blood cell salvage and autologous transfusion during open radical retropubic prostatectomy: a cost–benefit analysis

Should intraoperative cell-salvaged blood be used in patients with suspected or known malignancy?

Contact Info

Product

Resources

About